Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 700Neoplasms 621Prostatic Neoplasms 322Lung Neoplasms 314Colorectal Neoplasms 284Carcinoma, Non-Small-Cell Lung 260Pancreatic Neoplasms 181Carcinoma, Hepatocellular 171Stomach Neoplasms 141Multiple Myeloma 127Ovarian Neoplasms 123Melanoma 118Colonic Neoplasms 114Brain Neoplasms 111Hematologic Neoplasms 107Urinary Bladder Neoplasms 104Head and Neck Neoplasms 104Leukemia, Myeloid, Acute 102Esophageal Neoplasms 100Disease 100Uterine Cervical Neoplasms 91Liver Neoplasms 91Neoplasm Metastasis 89Lymphoma 86Rectal Neoplasms 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 84Endometrial Neoplasms 79Carcinoma, Renal Cell 74Leukemia 65Recurrence 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × HER2-positive Metastatic Breast Cancer × 1 year × Clear all
NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡